SCHEMBL25837924

SCHEMBL25837924

O=C(O)c1ccc([N+](=O)[O-])cc1[18F]

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.64
TDP1 Q9NUW8 2/20 0.64
CYP3A4 P08684 1/20 0.64
ALOX15 P16050 1/20 0.64
MAPT P10636 3/20 0.54
HIF1A Q16665 1/20 0.52
KMT2A Q03164 3/20 0.50
TP53 P04637 2/20 0.50
HTT P42858 1/20 0.50
MEN1 O00255 1/20 0.50
GAA P10253 1/20 0.50
CTSV O60911 1/20 0.50
CTSL P07711 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.49
MAOA P21397 1/20 0.49
MAOB P27338 1/20 0.49
CES2 O00748 1/20 0.47
MPO P05164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL77925 1.00 ALDH1A1 (0.64) ALDH1A1TDP1CYP3A4ALOX15MAPT
Hydrochloric Acid SCHEMBL17164230 0.98 ALDH1A1 (0.62) ALDH1A1TDP1CYP3A4ALOX15MAPT
SCHEMBL28281577 0.93 ALDH1A1 (0.57) ALDH1A1TDP1CYP3A4ALOX15MAPT
SCHEMBL28612092 0.89 ALDH1A1 (0.54) ALDH1A1TDP1CYP3A4ALOX15MAPT
SCHEMBL1654660 0.85 ALDH1A1 (0.59) ALDH1A1TDP1CYP3A4ALOX15MAPT
SCHEMBL195145 0.85 ALDH1A1 (0.59) ALDH1A1TDP1CYP3A4ALOX15MAPT
SCHEMBL887048 0.84 ALDH1A1 (0.57) ALDH1A1TDP1CYP3A4ALOX15MAPT
SCHEMBL31509357 0.84 MAPT (0.56) ALDH1A1TDP1CYP3A4ALOX15MAPT
SCHEMBL947293 0.84 ALDH1A1 (0.52) ALDH1A1TDP1CYP3A4ALOX15MAPT
SCHEMBL1360146 0.84 MAPT (0.56) ALDH1A1TDP1CYP3A4ALOX15MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240115221-A1 POSITRON IMAGING TOMOGRAPHY IMAGING AGENT COMPOSITION ADN METHOD FOR BACTERIAL INFECTION THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2024-04-11 US disclosed
US-11857352-B2 Positron imaging tomography imaging agent composition and method for bacterial infection THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2024-01-02 US disclosed
US-11857352-B2 Positron imaging tomography imaging agent composition and method for bacterial infection THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2024-01-02 US disclosed
US-20230226228-A1 POSITRON IMAGING TOMOGRAPHY IMAGING AGENT COMPOSITION AND METHOD FOR DETECTION OF BACTERIAL INFECTION THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2023-07-20 US disclosed
US-20230226228-A1 POSITRON IMAGING TOMOGRAPHY IMAGING AGENT COMPOSITION AND METHOD FOR DETECTION OF BACTERIAL INFECTION THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11857352-B2 Positron imaging tomography imaging agent composition and method for bacterial infection SLC6A19, SLC1A5, TMEM14C ALDH1A1 3952/4885TDP1 4584/4885CYP3A4 3587/4885
US-20230226228-A1 POSITRON IMAGING TOMOGRAPHY IMAGING AGENT COMPOSITION AND METHOD FOR DETECTION OF BACTERIAL INFECTION TLR5, SLC10A2, FNTB ALDH1A1 3223/4885TDP1 3881/4885CYP3A4 1495/4885
US-20240115221-A1 POSITRON IMAGING TOMOGRAPHY IMAGING AGENT COMPOSITION ADN METHOD FOR BACTERIAL INFECTION SLC6A19, SLC1A5, FLNB ALDH1A1 2596/4885TDP1 4704/4885CYP3A4 3992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.